DISCOVER FINANCE

Artificial intelligence has already made its impact on sectors ranging from financial services to software development. Now, investors are betting it could revolutionize one of the most expensive and uncertain industries: pharmaceutical drug discovery. On October 8, 2026, Nvidia-backed biotechnology company Iambic Therapeutics announced its intent to launch an IPO, with a goal of raising up to $159.4 million. This potentially values the company at around $806 million. The co

The stock market often seems to grab the largest amount of investor attention, yet this week one of the biggest moves happened elsewhere. On Thursday, October 1st, the yield on the 10-year U.S. Treasury reached 5.34%, which is its highest level since 2002. Treasury yields represent the return that investors demand to lend money to the U.S. government. Recently, investors have been selling bonds over concerns about inflation, oil prices, economic growth, and an increase in go

September is typically one of Wall Street’s busiest months for initial public offerings, but this year, it fell extremely short of expectations. The fall IPO market has stumbled out of the gate, with only three sizable companies entering the public market following Labor Day as of September 22. Many companies that planned to do the same in this fall window have begun to rethink their strategy. For example, Nuclear services company Holtec Nuclear and CVC-backed Bamboo Insuran

GRAIL shares surged this week as it received a major regulatory boost for Galleri, its blood test capable of detecting over 50 types of cancers from a single blood draw. On September 23, 2026, an FDA advisory committee voted 10-0 that Galleri is safe and 6-4 that it is effective. Maybe more critical for its future success, however, the panel voted 7-2 that the test’s benefits outweigh its risks for adults 50 years or older. The FDA is not required to follow these decisions m

A decade ago, large pharmaceutical companies looked to biotech hubs in the United States and Europe for their next blockbuster drugs. It appears that now, China has overtaken this role. On September 15, 2026, GSK agreed to a deal potentially valued at up to $750 million to acquire global rights to an experimental cancer drug from the privately held Chinese biotech company Chimagen Biosciences. The drug is a trispecific T-cell engager for multiple myeloma that has not even en

For generations, the path for young bankers entering Wall Street was, for the most part, similar. Late nights with heads buried in PowerPoint decks, analyzing numbers and spreadsheets that made heads spin, creating financial statements that stretched pages. But what OpenAI just created may mean humans no longer need to do this work. On September 10, 2026, OpenAI launched ChatGPT for Financial Services. In coordination with Morgan Stanley and Evercore, the system serves as a